CoChat

Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients

Madic, Jordan, Kiialainen, Anna, Bidard, Francois‐Clement, Birzele, Fabian, Ramey, Guillemette, Leroy, Quentin, Frio, Thomas Rio, Vaucher, Isabelle, Raynal, Virginie, Bernard, Virginie, Lermine, Alban, Clausen, Inga, Giroud, Nicolas, Schmucki, Roland, Milder, Maud, Horn, Carsten, Spleiss, Olivia, Lantz, Olivier, Stern, Marc‐Henri, Pierga, Jean‐Yves, Weisser, Martin, Lebofsky, Ronald · 2015 · International Journal of Cancer
Cited by 147

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Circulating tumor DNA (ctDNA) is a new circulating tumor biomarker which might be used as a prognostic biomarker in a way similar to circulating tumor cells (CTCs). Here, we used the high prevalence of TP53 mutations in triple negative breast cancer (TNBC) to compare ctDNA and CTC detection rates and prognostic value in metastatic TNBC patients. Forty patients were enrolled before starting a new line of treatment. TP53 mutations were characterized in archived tumor tissues and in plasma DNA using two next generation sequencing (NGS) platforms in parallel. Archived tumor tissue was sequenced successfully for 31/40 patients. TP53 mutations were found in 26/31 (84%) of tumor samples. The same mutation was detected in the matched plasma of 21/26 (81%) patients with an additional mutation found only in the plasma for one patient. Mutated allele fractions ranged from 2 to 70% (median 5%). The observed correlation between the two NGS approaches (R2 = 0.903) suggested that ctDNA levels data were quantitative. Among the 27 patients with TP53 mutations, CTC count was ≥1 in 19 patients (70%) and ≥5 in 14 patients (52%). ctDNA levels had no prognostic impact on time to progression (TTP) or overall survival (OS), whereas CTC numbers were correlated with OS (p = 0.04) and marginally with TTP (p = 0.06). Performance status and elevated LDH also had significant prognostic impact. Here, absence of prognostic impact of baseline ctDNA level suggests that mechanisms of ctDNA release in metastatic TNBC may involve, beyond tumor burden, biological features that do not dramatically affect patient outcome.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ijc.29265

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 147

Metadata

Authors
Madic, J., Kiialainen, A., Bidard, F., Birzele, F., Ramey, G., Leroy, Q., Frio, T. R., Vaucher, I., Raynal, V., Bernard, V., Lermine, A., Clausen, I., Giroud, N., Schmucki, R., Milder, M., Horn, C., Spleiss, O., Lantz, O., Stern, M., Pierga, J., Weisser, M., & Lebofsky, R.
Venue
International Journal of Cancer
Publisher
Wiley
Published
2014-10-23
Volume
136
Issue
9
Pages
2158-2165
ISSN
  • 0020-7136 (ISSN-L)
  • 1097-0215
OpenAlex
W1528629181
Cited by
147
References
4
FWCI
5.25
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients. https://app.cochat.ai/papers/10.1002/ijc.29265
The paper
Madic, J., Kiialainen, A., Bidard, F., Birzele, F., Ramey, G., Leroy, Q., Frio, T. R., Vaucher, I., Raynal, V., Bernard, V., Lermine, A., Clausen, I., Giroud, N., Schmucki, R., Milder, M., Horn, C., Spleiss, O., Lantz, O., Stern, M., . . . Lebofsky, R. (2015). Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients. International Journal of Cancer. https://doi.org/10.1002/ijc.29265

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.